Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer

被引:135
作者
Straver, Marieke E.
Meijnen, Philip
van Tienhoven, Geertjan
van de Velde, Cornelis J. H.
Mansel, Robert E.
Bogaerts, Jan
Demonty, Gaston
Duez, Nicole
Cataliotti, Luigi
Klinkenbijl, Jean
Westenberg, Helen A.
van der Mijle, Huub
Hurkmans, Coen
Rutgers, Emiel J. T. [1 ]
机构
[1] Netherlands Canc Inst, Dept Surg Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
POSTOPERATIVE RADIOTHERAPY; OPERABLE CANCER; TRIAL; VALIDATION; WOMEN; CHEMOTHERAPY; DISSECTION; SIGNATURE; TAMOXIFEN; CONSENSUS;
D O I
10.1200/JCO.2008.21.7554
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The After Mapping of the Axilla: Radiotherapy or Surgery? (AMAROS) phase III study compares axillary lymph node dissection (ALND) and axillary radiation therapy (ART) in early breast cancer patients with tumor-positive sentinel nodes. In the ART arm, the extent of nodal involvement remains unknown, which could have implications on the administration of adjuvant therapy. In this preliminary analysis, we studied the influence of random assignment to ALND or ART on the choice for adjuvant treatment. Patients and Methods In the first 2,000 patients enrolled in the AMAROS trial, we analyzed the administration of adjuvant systemic therapy. Multivariate analysis was used to assess variables affecting the administration of adjuvant chemotherapy. Adjuvant therapy was applied according to institutional guidelines. Results Of 2,000 patients, 566 patients had a positive sentinel node and were treated per random assignment. There was no significant difference in the administration of adjuvant systemic therapy. In the ALND and ART arms, 58% (175 of 300) and 61% (162 of 266) of the patients, respectively, received chemotherapy. Endocrine therapy was administered in 78% (235 of 300) of the patients in the ALND arm and in 76% (203 of 266) of the patients in the ART arm. Treatment arm was not a significant factor in the decision, and no interactions between treatment arm and other factors were observed. Multivariate analysis showed that age, tumor grade, multifocality, and size of the sentinel node metastasis significantly affected the administration of chemotherapy. Within the ALND arm, the extent of nodal involvement remained not significant in a sensitivity multivariate analysis. Conclusion Absence of knowledge regarding the extent of nodal involvement in the ART arm appears to have no major impact on the administration of adjuvant therapy.
引用
收藏
页码:731 / 737
页数:7
相关论文
共 50 条
  • [41] Axillary management in patients with clinical node-negative early breast cancer and positive sentinel lymph node: a systematic review and meta-analysis
    Li, Changzai
    Zhang, Pan
    Lv, Jie
    Dong, Wei
    Hu, Baoshan
    Zhang, Jinji
    Zhu, Hongcheng
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [42] The significance of sentinel lymph node micrometastasis in breast cancer: Comparing outcomes with and without axillary clearance
    Youssef, Mina M. G.
    Cameron, Diane
    Pucher, Philip H.
    Olsen, Sisse
    Ferguson, Douglas
    BREAST, 2016, 30 : 101 - 104
  • [43] Sentinel Node Biopsy After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Does Axillary Ultrasound Improve Performance?
    Mautner, Starr Koslow
    Cody, Hiram S., III
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (30) : 3375 - +
  • [44] Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation
    Takei, Hiroyuki
    Yoshida, Takashi
    Kurosumi, Masafumi
    Inoue, Kenichi
    Matsumoto, Hiroshi
    Hayashi, Yuji
    Higuchi, Toru
    Uchida, Sayaka
    Ninomiya, Jun
    Kubo, Kazuyuki
    Oba, Hanako
    Nagai, Shigenori
    Tabei, Toshio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 547 - 553
  • [45] Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs, Andre
    Koepke, Melitta
    Feisst, Manuel
    Riedel, Fabian
    Rezai, Mahdi
    Nitz, Ulrike
    Moderow, Mareike
    Golatta, Michael
    Sohn, Christof
    Schneeweiss, Andreas
    Heil, Joerg
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) : 429 - 438
  • [46] Axillary recurrences after sentinel lymph node biopsy in initial breast cancer
    Sampol, C.
    Gimenez, M.
    Torrecabota, J.
    Serra, C.
    Canet, R.
    Daumal, J.
    Pena, C.
    Gonzalez, L.
    Hernandez, E.
    Graner, A.
    Pozo, A.
    Vega, F.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2010, 29 (05): : 241 - 245
  • [47] Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer
    Andersson, Y.
    de Boniface, J.
    Jonsson, P. -E.
    Ingvar, C.
    Liljegren, G.
    Bergkvist, L.
    Frisell, J.
    BRITISH JOURNAL OF SURGERY, 2012, 99 (02) : 226 - 231
  • [48] Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?
    Garrido-Castro, Ana C.
    Winer, Eric P.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (04):
  • [49] Positive non-sentinel axillary lymph nodes in breast cancer with 1-2 sentinel lymph node metastases
    Zheng, Jianwei
    Cai, Shuyan
    Song, Huimin
    Wang, Yunlei
    Han, Xiaofeng
    Wu, Haoliang
    Gao, Zhigang
    Qiu, Fanrong
    MEDICINE, 2018, 97 (44)
  • [50] Axillary nodal metastases in Italian early breast cancer patients with positive sentinel lymph node: can axillary node dissection be avoided by using predictive nomograms?
    Biolchini, Federico
    Vicentini, Massimo
    Di Felice, Enza
    Giovanardi, Filippo
    Antonio, Lucchini
    Rossi, Paolo Giorgi
    Annessi, Valerio
    TUMORI JOURNAL, 2015, 101 (03): : 298 - 305